Targeted drug vismodegib tested against rare genetic cancers
NCT ID NCT06357988
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests the drug vismodegib in 34 patients with advanced solid tumors, lymphoma, or multiple myeloma that have specific mutations in the SMO or PTCH1 genes. Vismodegib works by blocking a protein involved in cell growth. The main goal is to see if the drug can shrink or stop the growth of these cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Vismodegib (Erivedge)
- What this could lead to
- If successful, this could point toward a targeted treatment option for patients with certain hard-to-treat cancers that have specific genetic mutations.
- What could go wrong
- This is a small, early-phase trial (34 participants) with no control group, so results may not apply broadly. The drug may not shrink tumors or improve survival, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered donor cells could outsmart relapsed myeloma
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can a protein calm the immune System's overreaction to cancer treatment?
- A virtual pharmacy visit may ease opioid fears for cancer patients
- Can meditation tame the Long-Term side effects of a stem cell transplant?
- Strumming through treatment: can ukulele lessons shield teen brains from Radiation's toll?